Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377959> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4381377959 abstract "The increasing prevalence of childhood overweight and obesity has led to a substantial increase in T2D in youth. The clinical course of youth-onset T2D is more aggressive than in adults, with a faster decline in beta‑cell function leading to worse glycemic control and an early onset of complications. The DINAMO trial compared the efficacy and safety of empagliflozin and linagliptin with placebo in 157 participants aged 10-17 years. Participants were randomized (1:1:1) to linagliptin 5 mg, empagliflozin 10 mg, or placebo. At Week 12, those in the empagliflozin group who did not attain HbA1c <7.0% were re‑randomized (1:1) to empagliflozin 10 or 25 mg. Responders were defined as having no rescue medication and a HbA1c change from baseline ≤-0.5% or attained HbA1c <7.0% at Week 26. Empagliflozin results were pooled. Significantly more participants responded to empagliflozin vs placebo (rate difference 23.6, 95% CI 4.3-41.4; p=0.01); this response was maintained to Week 52 by 40% of the group. Results for linagliptin vs placebo were not significant. Empagliflozin provided a clinically meaningful response even at higher HbA1c and FPG levels (Table). These results show that empagliflozin provides a clinically relevant, statistically significant, and durable improvement in glycemic control, suggesting SGLT2 inhibitors could be a new therapy for T2D in youth. Disclosure L. M. Laffel: Advisory Panel; Medtronic, Lilly Diabetes, Novo Nordisk, Vertex Pharmaceuticals Incorporated, Roche Diagnostics, Provention Bio, Inc., Consultant; Dexcom, Inc., Janssen Pharmaceuticals, Inc., Medscape. T. Danne: Research Support; Abbott Diabetes, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Medtronic, Stock/Shareholder; DreaMed Diabetes, Ltd. W. V. Tamborlane: None. G. J. Klingensmith: Advisory Panel; Boehringer Ingelheim Inc., Consultant; AstraZeneca, Boehringer Ingelheim Inc., Novo Nordisk, Takeda Pharmaceutical Co., Ltd. D. Neubacher: Employee; Boehringer Ingelheim Pharma GmbH&Co. KG. I. Tartakovsky: Employee; Boehringer Ingelheim International GmbH. J. Marquard: Employee; Boehringer Ingelheim Inc. P. Zeitler: Consultant; Eli Lilly and Company, Boehringer Ingelheim Inc., Johnson & Johnson. S. M. Willi: Advisory Panel; Boehringer Ingelheim International GmbH, Medtronic. Funding Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance" @default.
- W4381377959 created "2023-06-21" @default.
- W4381377959 creator A5002265183 @default.
- W4381377959 creator A5008321592 @default.
- W4381377959 creator A5012566469 @default.
- W4381377959 creator A5042310463 @default.
- W4381377959 creator A5047359258 @default.
- W4381377959 creator A5063640226 @default.
- W4381377959 creator A5069785394 @default.
- W4381377959 creator A5086892883 @default.
- W4381377959 creator A5089738768 @default.
- W4381377959 date "2023-06-20" @default.
- W4381377959 modified "2023-09-24" @default.
- W4381377959 title "164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo" @default.
- W4381377959 doi "https://doi.org/10.2337/db23-164-lb" @default.
- W4381377959 hasPublicationYear "2023" @default.
- W4381377959 type Work @default.
- W4381377959 citedByCount "0" @default.
- W4381377959 crossrefType "journal-article" @default.
- W4381377959 hasAuthorship W4381377959A5002265183 @default.
- W4381377959 hasAuthorship W4381377959A5008321592 @default.
- W4381377959 hasAuthorship W4381377959A5012566469 @default.
- W4381377959 hasAuthorship W4381377959A5042310463 @default.
- W4381377959 hasAuthorship W4381377959A5047359258 @default.
- W4381377959 hasAuthorship W4381377959A5063640226 @default.
- W4381377959 hasAuthorship W4381377959A5069785394 @default.
- W4381377959 hasAuthorship W4381377959A5086892883 @default.
- W4381377959 hasAuthorship W4381377959A5089738768 @default.
- W4381377959 hasConcept C126322002 @default.
- W4381377959 hasConcept C134018914 @default.
- W4381377959 hasConcept C142724271 @default.
- W4381377959 hasConcept C168563851 @default.
- W4381377959 hasConcept C204787440 @default.
- W4381377959 hasConcept C27081682 @default.
- W4381377959 hasConcept C2775887513 @default.
- W4381377959 hasConcept C2777180221 @default.
- W4381377959 hasConcept C2779306644 @default.
- W4381377959 hasConcept C2780031085 @default.
- W4381377959 hasConcept C2780473172 @default.
- W4381377959 hasConcept C555293320 @default.
- W4381377959 hasConcept C67761136 @default.
- W4381377959 hasConcept C71924100 @default.
- W4381377959 hasConceptScore W4381377959C126322002 @default.
- W4381377959 hasConceptScore W4381377959C134018914 @default.
- W4381377959 hasConceptScore W4381377959C142724271 @default.
- W4381377959 hasConceptScore W4381377959C168563851 @default.
- W4381377959 hasConceptScore W4381377959C204787440 @default.
- W4381377959 hasConceptScore W4381377959C27081682 @default.
- W4381377959 hasConceptScore W4381377959C2775887513 @default.
- W4381377959 hasConceptScore W4381377959C2777180221 @default.
- W4381377959 hasConceptScore W4381377959C2779306644 @default.
- W4381377959 hasConceptScore W4381377959C2780031085 @default.
- W4381377959 hasConceptScore W4381377959C2780473172 @default.
- W4381377959 hasConceptScore W4381377959C555293320 @default.
- W4381377959 hasConceptScore W4381377959C67761136 @default.
- W4381377959 hasConceptScore W4381377959C71924100 @default.
- W4381377959 hasIssue "Supplement_1" @default.
- W4381377959 hasLocation W43813779591 @default.
- W4381377959 hasOpenAccess W4381377959 @default.
- W4381377959 hasPrimaryLocation W43813779591 @default.
- W4381377959 hasRelatedWork W2137986270 @default.
- W4381377959 hasRelatedWork W2140480989 @default.
- W4381377959 hasRelatedWork W2314880155 @default.
- W4381377959 hasRelatedWork W2330830805 @default.
- W4381377959 hasRelatedWork W2406886656 @default.
- W4381377959 hasRelatedWork W2758610685 @default.
- W4381377959 hasRelatedWork W3087822011 @default.
- W4381377959 hasRelatedWork W3117802259 @default.
- W4381377959 hasRelatedWork W4233501496 @default.
- W4381377959 hasRelatedWork W4318833121 @default.
- W4381377959 hasVolume "72" @default.
- W4381377959 isParatext "false" @default.
- W4381377959 isRetracted "false" @default.
- W4381377959 workType "article" @default.